FDA Panel Wants Anemia Drug Warnings
Experts Concerned Drugs Are Overprescribed Despite Risks
WebMD News Archive
Most evidence suggests that the increased risks are the result not of
recommended use, but instead are due to overdosing and overprescribing to a
largely unstudied swath of patients. As many as 450,000 American patients are
taking the drugs, which can cost $1,000 per treatment.
Many doctors prescribe the drugs to improve quality of life by helping with
the fatigue often resulting from anemia. But FDA scientists said Thursday that
no scientific studies have shown the drugs improve cancer patients' quality of
At the same time, evidence from at least two recent studies showed they may
promote tumors and cause early death, says Vinni Juneja, an agency safety
"FDA believes there should be a reconsideration of the risk to benefit
ratio ... in cancer patients," he says.
Industry scientists maintain that the drugs can improve quality of life and
don't spur cancer growth.
"We do not have data that tumor progression is an issue as a result of
erythropoietin treatment. We simply don't," says Roger M. Perlmutter, MD,
executive vice president of Amgen, which sells Epogen.
But agency officials and experts blamed aggressive industry marketing for
promoting the drugs as a way to boost energy -- a claim not approved by the
Television and print advertisements widely distributed by Procrit maker
Johnson & Johnson urged patients to seek out the drug as a way to improve
"Most doctors and most patients think this drug has been approved
because it improves quality of life, it improves fatigue. There's a lot of
sleight of hand here on how the drug is used ... and that's a problem,"
says Otis Brawley, MD, a professor of oncology at Winship Cancer Institute at
Emory University in Atlanta and a member of the panel.
Maha H.A. Hussein, MD, the panel's chairwoman, says she doesn't want to see
the drugs pulled from the market because they are important for "supportive
care." But she also suggests that company marketing has urged doctors to
give higher-than-recommended doses under the assumption that boosting red blood
cell counts translated to more comfort for patients.